TrialPath

Find a study

Match me to a study

321 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

148 studies on the map

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamA Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Cahaba Research, Inc. - Trussville Location, BirminghamA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) — AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, AvondaleA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, EncinoA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamStudy of ALTO-300 in MDD — Site 200, PhoenixA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiA Study of LY4064912 in Healthy Participants and With Overweight or Obesity — Collaborative Neuroscience Network - CNS, Los AlamitosModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonOxytocin for Weight Loss in Adolescents — Massachusetts General Hospital, BostonA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Medical Dermatology Specialists, PhoenixKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborConvergent Mechanisms Underlying Reprometabolic Syndrome in Women — University of Colorado School of Medicine, AuroraDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiProbiotic Administration for Adolescent Depression — UCSF, San FranciscoAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkMood Effects of Serotonin Agonists: Depression — University of Chicago, ChicagoNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaGlutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine — Emory University, AtlantaExamining the Effects of Estradiol on Neural and Molecular Response to Reward — University of North Carolina at Chapel Hill, Chapel HillInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonNeural Circuit Effects of Ketamine in Depression — Icahn School of Medicine at Mount Sinai, New YorkSleep Health in U.S. Marines — San Diego State University, San DiegoNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLeucine in Midlife Depression — Emory University Hospital, AtlantaFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, Columbus5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityPET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. — Stony Brook University: Dept of Psychiatry, Stony BrookModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityA Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Arizona Clinical Trials-Chandler, ChandlerA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenJAK Signaling in Depression — Emory University, AtlantaIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, AtlantaTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los Angeles[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusSynaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — McLean Hospital, BelmontPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonThe Role of mGluR5 in CBT-I — Stony Brook University: Dept of Psychiatry, Stony BrookAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattleClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoCannabidiol for Reduction of Brain Neuroinflammation — Massachusetts General Hospital, BostonEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkConfirmatory Efficacy Trial of Attention Bias Modification for Depression — Institute for Mental Health Research, AustinA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients — Mayo Clinic Florida, JacksonvilleALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerEfficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity — Kailera Clinical Site, ChandlerA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertCaloric Restriction and Activity to Reduce Chemoresistance in B-ALL — Children's Hospital Los Angeles, Los AngelesACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksDBS for Depression — Zucker Hillside Hospital, QueensA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity — MBX Biosciences Investigational Site, DoralSodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) — NYU Langone Health, New YorkEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GroveA Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachTirzepatide in PWS, HO and GNSO — Children's Minnesota, Saint PaulA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. — Research Site, GlendaleStudy of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) — Qps-Mra, Llc., MiamiACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimorePersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine — University of Pennsylvania, PhiladelphiaA Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity — Altasciences Clinical LA, Inc., CypressImaging Depression in Parkinson's Disease — Yale University, New HavenMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. — Monroe Biomedical Research, LouisvilleOvarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression — University of North Carolina, Chapel Hill, Chapel HillA Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity — CenExel ACT- Anaheim Clinical Trials /ID# 283200, AnaheimEfficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity — The Children's Hospital of Philadelphia, PhiladelphiaA Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets — Corxel Investigational site, Las VegasPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontRNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) — Mayo Clinic in Rochester, RochesterSerotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures — Wake Forest University Health Sciences, Winston-SalemRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los Angeles

Showing the 150 nearest — narrow your filters for fewer, closer studies.